Inogen, Inc.

NasdaqGS:INGN 株式レポート

時価総額：US$173.5m

Inogen 過去の業績

過去 基準チェック /06

Inogenの収益は年間平均-10.1%の割合で減少していますが、 Medical Equipment業界の収益は年間 増加しています。収益は年間13.6% 0.3%割合で 減少しています。

主要情報

-10.07%

収益成長率

-8.78%

EPS成長率

Medical Equipment 業界の成長8.90%
収益成長率-0.29%
株主資本利益率-13.61%
ネット・マージン-7.08%
前回の決算情報31 Mar 2026

最近の業績更新

Recent updates

ナラティブの更新 • May 09

INGN: Bullish Initiation And Buyback Program Will Support Future Upside

Analysts have trimmed their price target on Inogen from about $13.00 to roughly $12.67, reflecting updated assumptions around revenue, profit margins and future P/E following fresh bullish initiation research from the Street. Analyst Commentary Analysts are using the fresh bullish initiation as a chance to refresh their models, focus on execution and reassess how much they are willing to pay for Inogen at the current P/E.
ナラティブの更新 • Apr 19

INGN: Buybacks And New Leadership Will Support Future Returns

Analysts have adjusted their price target on Inogen to $12.00, reflecting updated views on revenue growth assumptions, profit margin expectations, and the valuation multiple following recently published Street research, including a positive initiation of coverage. Analyst Commentary Recent Street research on Inogen has combined a constructive long term narrative with a more restrained tone on execution risks and how much investors are currently being asked to pay for that story.
ナラティブの更新 • Apr 04

INGN: Sleep Therapy Expansion And Buybacks Will Support Future Returns

Analysts have adjusted their price target on Inogen to $12.00, reflecting updated assumptions around the discount rate, revenue growth, profit margin, and future P/E, which keep the fair value view broadly in line with prior estimates. What's in the News Inogen appointed Jason Richardson as Chief Financial Officer, effective April 6, 2026, succeeding Michael Bourque, who will remain in an advisory role until June 30, 2026 (Key Developments).
ナラティブの更新 • Mar 21

INGN: Sleep Therapy Expansion And Buybacks Will Support Future Earnings Power

Analysts have maintained their price target for Inogen at $12.00, making small adjustments to assumptions around the discount rate, revenue growth, profit margin, and future P/E, which together result in an unchanged fair value view. What's in the News Inogen approved a share repurchase program of up to US$30 million of its common stock, funded by cash flow and existing cash reserves, with an expiry on the earlier of December 31, 2027, or when the full amount is used (Key Developments).
ナラティブの更新 • Mar 06

INGN: Sleep Therapy Expansion And Buybacks Will Support Future Undervalued Upside

Analysts maintained their fair value estimate for Inogen at $13.00, citing slightly adjusted assumptions around the discount rate, revenue growth, profit margin, and future P/E that refine rather than significantly change their prior view. What's in the News Inogen announced a share repurchase program authorizing the company to buy back up to US$30 million of its common stock, funded by cash flow and existing cash reserves, with the program running until the earlier of December 31, 2027, or when the full amount is used (Key Developments).
ナラティブの更新 • Feb 20

INGN: Sleep Therapy Portfolio Expansion Will Support Future Earnings Power

Analysts have adjusted their price target on Inogen to $12.00. The change reflects updated assumptions around discount rate, revenue growth, profit margin and future P/E expectations.
ナラティブの更新 • Feb 06

INGN: Sleep Therapy Expansion Will Support Future Confidence In Undervalued Shares

Analysts have kept their price target for Inogen steady at US$13.00. This reflects only minor tweaks to assumptions for discount rate, revenue growth, profit margin, and future P/E that do not materially change their overall view of the stock.
ナラティブの更新 • Jan 22

INGN: Sleep Therapy Expansion Will Support Future Earnings Power Ahead

Narrative Update on Inogen Analysts have modestly adjusted their price target on Inogen to reflect updated assumptions for discount rate, revenue growth, profit margin and future P/E. This has led to a refined valuation that still centers around a fair value of $12.00 per share.
ナラティブの更新 • Jan 08

INGN: Stable Guidance And New Respiratory Line Will Support Future Confidence

Analysts have kept their price target for Inogen broadly in line with prior views, with only a small adjustment supported by updated assumptions around discount rate, profit margin and future P/E expectations, rather than any major shift in the outlook. What's in the News Inogen launched Aurora CPAP masks as a new product line within its respiratory care portfolio, targeting patients with obstructive sleep apnea through the F1 Full Face, N1 Nasal Cushion, and P1 Nasal Pillows range (Key Developments).
ナラティブの更新 • Dec 16

INGN: Rising Revenue Outlook Will Support Stronger Earnings Power Ahead

Analysts have raised their price target on Inogen by approximately $5 to around $12 per share, reflecting modestly higher expectations for revenue growth, profit margins, and future earnings multiples, despite a slightly higher assumed discount rate. What's in the News Issued new fourth quarter 2025 revenue guidance of $87 million to $90 million, implying roughly 10% year over year growth at the midpoint compared to fourth quarter 2024 (company guidance) Reiterated full year 2025 revenue outlook of $354 million to $357 million, targeting about 6% growth at the midpoint versus 2024 revenue (company guidance) Emphasized that the updated outlook reflects confidence in execution while maintaining a disciplined view of demand and pricing conditions in the portable oxygen concentrator market (company guidance) Valuation Changes The fair value estimate has risen materially, increasing from approximately $7.00 to $12.00 per share.
ナラティブの更新 • Dec 02

INGN: Guidance Stability Will Drive Confidence As Margins Poised To Improve

Analysts have maintained their price target for Inogen at $13.00. This reflects minimal changes in financial assumptions and a steady outlook for the company's revenue growth and profitability.
ナラティブの更新 • Nov 18

INGN: Profit Margins Will Strengthen As Revenue Guidance Remains Encouraging

Analysts have adjusted Inogen’s price target to $13.00. This is a slight change that reflects expectations of improved profit margins, despite modest revisions in growth rates and valuation metrics.
Seeking Alpha • Nov 11

Slow Progress At Inogen ... But Progress All The Same

Summary Inogen (INGN) continues its turnaround, showing progress in revenue growth and margins, but the pace remains slower and riskier than the market desires. INGN posted positive adjusted EBITDA and raised full-year guidance, despite mixed quarterly results and ongoing volatility in direct-to-consumer and rental segments. The company’s strong market position, new product launches, and partnerships offer long-term growth potential, especially as patients consistently prefer portable solutions. Valuation appears deeply discounted, with net cash and little credit for progress; INGN offers speculative upside for risk-tolerant investors if improvements persist. Read the full article on Seeking Alpha
ナラティブの更新 • Nov 03

INGN: Profit Margins Will Strengthen Amid Broader Respiratory Care Market Expansion

Analysts have slightly increased their price target for Inogen to $13.00 per share. This change reflects modest adjustments to profit margin forecasts and discount rates in their updated models.
ナラティブの更新 • Oct 20

Home And Outpatient Respiratory Care Will Expand Market Opportunities

Analysts have reaffirmed their price target for Inogen at $13.00, citing stable outlooks with only minor adjustments to key financial metrics. What's in the News Inogen issued new earnings guidance for the third quarter of 2025, projecting revenue between $91 million and $93 million.
ナラティブの更新 • Oct 05

Home And Outpatient Respiratory Care Will Expand Market Opportunities

Analysts have raised their price target for Inogen from $11.00 to $13.00, citing updated projections of slightly stronger revenue growth and reduced discount rates as key contributors to the increased valuation. What's in the News Inogen, Inc.
分析記事 • Aug 31

There's No Escaping Inogen, Inc.'s (NASDAQ:INGN) Muted Revenues Despite A 29% Share Price Rise

The Inogen, Inc. ( NASDAQ:INGN ) share price has done very well over the last month, posting an excellent gain of 29...
ナラティブの更新 • Aug 10

Home And Outpatient Respiratory Care Will Expand Market Opportunities

Despite an upward revision in revenue growth forecasts and a lower future P/E, the analyst consensus price target for Inogen has decreased from $11.67 to $11.00, indicating increased caution around the company’s fair value. What's in the News Inogen expects third quarter 2025 revenue of $91–93 million (~4% YoY growth) and full-year 2025 revenue of $354–357 million (~6% YoY growth).
分析記事 • May 10

Analysts Have Been Trimming Their Inogen, Inc. (NASDAQ:INGN) Price Target After Its Latest Report

A week ago, Inogen, Inc. ( NASDAQ:INGN ) came out with a strong set of quarterly numbers that could potentially lead to...
User avatar
新しいナラティブ • Apr 01

Yuwell Collaboration Will Open Chinese Respiratory Market

Strategic partnerships and product innovation in China and digital health are expected to drive growth and improve earnings potential.
分析記事 • Mar 08

Why Investors Shouldn't Be Surprised By Inogen, Inc.'s (NASDAQ:INGN) 35% Share Price Plunge

Inogen, Inc. ( NASDAQ:INGN ) shareholders won't be pleased to see that the share price has had a very rough month...
Seeking Alpha • Mar 01

A Volatile Share Price Masks Some Of The Progress At Inogen

Summary Inogen's new management and strategy are yielding results, with better-than-expected 2024 performance and a more stable base from which to keep growing the B2B business. Despite weak DTC sales, strong B2B growth drove better-than-expected sales in Q4, and Inogen likewise beat on margins. Guidance disappointed investors and prompted a 15% drop in the shares, as moderately better revenue guidance was offset by unexpected gross margin deleverage. Key recent developments include FDA approval of the Simeox device and a strategic partnership with Yuwell, both offering long-term growth potential but requiring time to ramp. While 2024 progress is promising and the valuation is not at all demanding, significant risks remain, particularly in revenue acceleration and margin leverage, making Inogen a high-risk but intriguing speculative investment. Read the full article on Seeking Alpha
分析記事 • Feb 28

Inogen, Inc. (NASDAQ:INGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$10.00

Shareholders in Inogen, Inc. ( NASDAQ:INGN ) had a terrible week, as shares crashed 23% to US$7.95 in the week since...
分析記事 • Jan 22

Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 32%

Inogen, Inc. ( NASDAQ:INGN ) shareholders would be excited to see that the share price has had a great month, posting a...
Seeking Alpha • Sep 24

Inogen: Upside Seems Limited After Big Move Up

Summary Inogen, Inc. manufactures portable oxygen concentrators and related accessories. The shares have doubled over the past year, but the equity is still trading at roughly 75% of annual sales. Despite an earnings beat in Q2, Wall Street analysts are cautious about the stock's current prospects. Inogen boasts a strong balance sheet with over $120 million in cash (which is roughly half the stock's market cap) and no long-term debt. An analysis of Inogen follows in the paragraphs below. Read the full article on Seeking Alpha
分析記事 • Jul 16

Inogen, Inc.'s (NASDAQ:INGN) Price Is Right But Growth Is Lacking After Shares Rocket 26%

Despite an already strong run, Inogen, Inc. ( NASDAQ:INGN ) shares have been powering on, with a gain of 26% in the...
Seeking Alpha • Jul 01

Inogen: Improving, But Still Struggling For Air

Summary Inogen aims to help millions suffering from COPD with portable oxygen delivery machines, but its financial performance has been inconsistent. Inogen faced execution issues, but recent improvements in operating momentum due to competitor exits and new management team are sparking optimism. Recent revenue growth, cost cuts, and narrowing losses are encouraging, but shares remain highly speculative and further progress is needed for a more positive outlook. Read the full article on Seeking Alpha
分析記事 • May 22

Inogen, Inc. (NASDAQ:INGN) Stock Catapults 28% Though Its Price And Business Still Lag The Industry

Inogen, Inc. ( NASDAQ:INGN ) shareholders are no doubt pleased to see that the share price has bounced 28% in the last...
Seeking Alpha • Apr 13

Inogen: New Management And A Major Competitor Exit Offer Some New Opportunities

Summary Inogen has continued to struggle, with growth in the rental business overshadowed by declines in direct-to-consumer sales, volatility in business-to-business sales, and pricing pressures. Inogen has the opportunity to leverage the exit of a major competitor, Philips, from the portable oxygen concentrator (POC) market. The new management team aims to position Inogen as the premium POC provider and partner with home medical equipment companies, while also focusing on the Physio-Assist opportunity. Inogen shares trade at a steep discount, but the Street typically wants nothing to do with low-growth small-cap med-tech, so management must present a credible plan for meaningful sustained growth. Read the full article on Seeking Alpha
分析記事 • Mar 01

Inogen, Inc. (NASDAQ:INGN) Just Reported, And Analysts Assigned A US$6.50 Price Target

There's been a major selloff in Inogen, Inc. ( NASDAQ:INGN ) shares in the week since it released its annual report...
分析記事 • Feb 01

Inogen, Inc. (NASDAQ:INGN) Held Back By Insufficient Growth Even After Shares Climb 25%

Despite an already strong run, Inogen, Inc. ( NASDAQ:INGN ) shares have been powering on, with a gain of 25% in the...

収支内訳

Inogen の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

NasdaqGS:INGN 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
31 Mar 26351-2516420
31 Dec 25349-2316319
30 Sep 25347-2516520
30 Jun 25343-2616819
31 Mar 25340-2716919
31 Dec 24336-3617222
30 Sep 24332-5317422
30 Jun 24327-9217023
31 Mar 24322-9716822
31 Dec 23316-10217021
30 Sep 23328-13317020
30 Jun 23349-9617820
31 Mar 23369-9018222
31 Dec 22377-8418022
30 Sep 22366-5017921
30 Jun 22353-2817020
31 Mar 22351-2016718
31 Dec 21358-616217
30 Sep 213561115516
30 Jun 21337-214715
31 Mar 21307-513614
31 Dec 20308-613614
30 Sep 20313-213514
30 Jun 20331613613
31 Mar 203601414111
31 Dec 19362211429
30 Sep 19370321448
30 Jun 19373421487
31 Mar 19369461447
31 Dec 18358521347
30 Sep 18335411207
30 Jun 18309321076
31 Mar 1827626965
31 Dec 1724921885
30 Sep 1723727815
30 Jun 1722225765
31 Mar 1721224725
31 Dec 1620321695
30 Sep 1619219675
30 Jun 1617917645
31 Mar 1616813604
31 Dec 1515912574
30 Sep 151489534
30 Jun 151369493

質の高い収益: INGNは現在利益が出ていません。

利益率の向上: INGNは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: INGNは利益が出ておらず、過去 5 年間で損失は年間10.1%の割合で増加しています。

成長の加速: INGNの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: INGNは利益が出ていないため、過去 1 年間の収益成長をMedical Equipment業界 ( 14.8% ) と比較することは困難です。

株主資本利益率

高いROE: INGNは現在利益が出ていないため、自己資本利益率 ( -13.61% ) はマイナスです。

総資産利益率

使用総資本利益率

過去の好業績企業の発掘

7D

1Y

7D

1Y

7D

1Y

企業分析と財務データの現状

データ最終更新日（UTC時間）
企業分析2026/05/22 09:13
終値2026/05/22 00:00
収益2026/03/31
年間収益2025/12/31

データソース

企業分析に使用したデータはS&P Global Market Intelligence LLC のものです。本レポートを作成するための分析モデルでは、以下のデータを使用しています。データは正規化されているため、ソースが利用可能になるまでに時間がかかる場合があります。

パッケージデータタイムフレーム米国ソース例
会社財務10年
  • 損益計算書
  • キャッシュ・フロー計算書
  • 貸借対照表
アナリストのコンセンサス予想+プラス3年
  • 予想財務
  • アナリストの目標株価
市場価格30年
  • 株価
  • 配当、分割、措置
所有権10年
  • トップ株主
  • インサイダー取引
マネジメント10年
  • リーダーシップ・チーム
  • 取締役会
主な進展10年
  • 会社からのお知らせ

* 米国証券を対象とした例であり、非米国証券については、同等の規制書式および情報源を使用。

特に断りのない限り、すべての財務データは1年ごとの期間に基づいていますが、四半期ごとに更新されます。これは、TTM（Trailing Twelve Month）またはLTM（Last Twelve Month）データとして知られています。詳細はこちら。

分析モデルとスノーフレーク

本レポートを生成するために使用した分析モデルの詳細は当社のGithubページでご覧いただけます。また、レポートの使用方法に関するガイドやYoutubeのチュートリアルも掲載しています。

シンプリー・ウォールストリート分析モデルを設計・構築した世界トップクラスのチームについてご紹介します。

業界およびセクターの指標

私たちの業界とセクションの指標は、Simply Wall Stによって6時間ごとに計算されます。

アナリスト筋

Inogen, Inc. 3 これらのアナリストのうち、弊社レポートのインプットとして使用した売上高または利益の予想を提出したのは、 。アナリストの投稿は一日中更新されます。9

アナリスト機関
Anderson SchockB. Riley Securities, Inc.
Ilya ZubkovFreedom Broker
Matthew MishanKeyBanc Capital Markets Inc.